CHINARES PHARMA's DC6001 tablets and metronidazole gel approved for clinical use and market launch

CHINARES PHARMA (03320.HK) announced that its subsidiary Beijing Shuanghe Runchuang Technology has received the "Drug Clinical Trial Approval Notice" for DC6001 tablets issued by the National Medical Products Administration. At the same time, the metronidazole gel of the group's subsidiary China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. has been approved for marketing by the National Medical Products Administration.

DC6001 tablets are intended for the treatment of Stargardt disease, a hereditary macular degeneration in adolescents.

Metronidazole is a broad-spectrum antibacterial drug that can effectively kill and inhibit anaerobic bacteria, with significant anti-inflammatory and immunomodulatory effects. It is suitable for the local treatment of inflammatory papules, pustular lesions, and rosacea erythema. It is also recommended as a first-line medication in domestic and international guidelines for rosacea. The gel formulation has good permeability, a refreshing skin feel, and is convenient to use, better meeting patients' needs for local treatment medications for the skin